134523-01-6

Basic information

• Product Name: ATORVASTATIN SODIUM
• Synonyms: ATORVASTATIN SODIUM;[R-(R',R')]-2-(4-Fluorophenyl)-3-phenyl-4-[(phenylamino)carbonyl]-5-(1-methylethyl)-1-H-pyrrol-1-(-dihydrogen)heptanoic acid sodium;(3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid sodium salt;(3R,5R)-Atorvastatin Sodium Salt;Atorvastatin Sodium 134523-01-6;(3R,5R)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid sodium salt
• CAS NO: 134523-01-6
• Molecular Formula: C₃₃H₃₄FN₂O₅*Na
• Molecular Weight: 580.62
• EINECS: 1806241-263-5
• Mol File: 134523-01-6.mol

Chemical Properties

• Boiling Point: 722.2±60.0 °C at 760 mmHg
• Flash Point: 390.6±32.9 °C
• Appearance: /
• Density: 1.2±0.1 g/cm³
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Methanol (Slightly), Water (Slightly)
• PKA: 4.46(at 25℃)
• CAS DataBase Reference: ATORVASTATIN SODIUM(CAS DataBase Reference)
• NIST Chemistry Reference: ATORVASTATIN SODIUM(134523-01-6)
• EPA Substance Registry System: ATORVASTATIN SODIUM(134523-01-6)

Safety Data

• Hazardous Substances Data: 134523-01-6(Hazardous Substances Data)

Usage

Uses

(3R,5R)-Atorvastatin Sodium Salt is an Atorvastatin impurity in bulk drug and tablets.

InChI:InChI=1/2C33H35FN2O5.Ca.Na/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;/q;;+2;/p-2/t2*26-,27-;;/m10../s1

Synthetic route

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid t-butyl ester (134395-00-9) → atorvastatin sodium (134523-01-6)

Conditions	Yield
With sodium hydroxide; water In 1,4-dioxane; tert-butyl methyl ether for 21h; Product distribution / selectivity; Heating / reflux;	97.7%
With methanol; sodium hydroxide; water In tert-butyl methyl ether for 21h; Product distribution / selectivity; Heating / reflux;	91%
With sodium hydroxide; water; tert-butyl alcohol In tert-butyl methyl ether for 21h; Product distribution / selectivity; Heating / reflux;	91%

ethyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate (1146977-93-6) → atorvastatin sodium (134523-01-6)

Conditions	Yield
With water; sodium hydroxide at 20℃; for 15h;	89%

lipitor (134523-03-8) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Stage #1: lipitor With hydrogenchloride In tetrahydrofuran; water at 20℃; Stage #2: With sodium hydroxide In methanol; water Heating / reflux;

4-fluorobenzaldehyde (459-57-4) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 4 steps 1: 2) NEt3 / 1) ethyl thiazolium catalyst / or with methyl thiazolium catalyst; 1) EtOH 2: 75 percent / pivalic acid / toluene; heptane; tetrahydrofuran / Heating 3: aq. HCl / methanol 4: aq. NaOH / methanol View Scheme

tert-butyl [(4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate (125971-86-0, 125995-13-3) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 3 steps 1: 75 percent / pivalic acid / toluene; heptane; tetrahydrofuran / Heating 2: aq. HCl / methanol 3: aq. NaOH / methanol View Scheme
Multi-step reaction with 3 steps 1: Acidic conditions 2: hydrogenchloride; methanol 3: sodium hydroxide / water View Scheme
Multi-step reaction with 3 steps 1: Trimethylacetic acid / toluene / 1 h / 105 - 110 °C / Industrial scale 2: hydrogenchloride / methanol; water / 0 - 30 °C / Industrial scale 3: water; sodium hydroxide / methanol / 2.5 h / 0 - 30 °C / Industrial scale View Scheme
Multi-step reaction with 3 steps 1: Trimethylacetic acid; diisopropylamine; tetra(n-butyl)ammonium hydrogensulfate / 40 h / 78 - 85 °C 2: hydrogenchloride; water / methanol / 25 - 30 °C 3: water; sodium hydroxide View Scheme

2-((4R, 6R)-6-cyanomethyl-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid tert-butyl ester (125971-94-0) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 4 steps 1: 95 percent / H2, ammonia / Molybdenum doped Raney nickel / methanol / 2585.7 Torr 2: 75 percent / pivalic acid / toluene; heptane; tetrahydrofuran / Heating 3: aq. HCl / methanol 4: aq. NaOH / methanol View Scheme
Multi-step reaction with 4 steps 1: hydrogen; nickel; ammonia / methanol 2: Acidic conditions 3: hydrogenchloride; methanol 4: sodium hydroxide / water View Scheme
Multi-step reaction with 4 steps 1: hydrogen; ammonia / cyclohexane; water / 30 - 40 °C / 3750.38 Torr / Autoclave 2: Trimethylacetic acid; diisopropylamine; tetra(n-butyl)ammonium hydrogensulfate / 40 h / 78 - 85 °C 3: hydrogenchloride; water / methanol / 25 - 30 °C 4: water; sodium hydroxide View Scheme

2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxopentanoic acid phenylamide (125971-96-2) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 3 steps 1: 75 percent / pivalic acid / toluene; heptane; tetrahydrofuran / Heating 2: aq. HCl / methanol 3: aq. NaOH / methanol View Scheme
Multi-step reaction with 2 steps 1.1: Trimethylacetic acid / n-heptane / 100 °C 2.1: hydrogenchloride; water / methanol / 25 - 30 °C 2.2: -10 °C View Scheme
Multi-step reaction with 3 steps 1: Trimethylacetic acid / toluene / 1 h / 105 - 110 °C / Industrial scale 2: hydrogenchloride / methanol; water / 0 - 30 °C / Industrial scale 3: water; sodium hydroxide / methanol / 2.5 h / 0 - 30 °C / Industrial scale View Scheme

tert-butyl (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate (125971-95-1) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 2 steps 1: aq. HCl / methanol 2: aq. NaOH / methanol View Scheme
Stage #1: tert-butyl (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate With hydroxylamine hydrochloride In methanol; water; acetone at 55 - 65℃; Industry scale; Stage #2: With sodium hydroxide In methanol; water at 35 - 45℃; Product distribution / selectivity;
Stage #1: tert-butyl (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate With hydrogenchloride; water In tetrahydrofuran at 25℃; for 6.25h; Industry scale; Stage #2: With sodium hydroxide In tetrahydrofuran at 31℃; for 14h; Product distribution / selectivity; Cooling;

[R(R*,R*)]-2-(4-fluorophenyl)-β,δ-di(tert-butyldimethylsiloxy)-5-(1-methylethyl)-3-phenyl-4-[(pheny)carbonyl]-1H-pyrrole-1-heptanoic acid test-butyl ester (697266-12-9) → atorvastatin sodium (134523-01-6)

Conditions	Yield
With sodium hydroxide In methanol; water for 6h; Heating / reflux;

atorvastatin (134523-00-5) → atorvastatin sodium (134523-01-6)

Conditions	Yield
With sodium hydroxide In water; acetonitrile at 20℃; for 144h;
With sodium hydroxide In water
With sodium hydroxide In water

(6-{2-[2-(4-fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrolidin-1-yl]-ethyl}-2-phenyl-[1,3,2] dioxaborinan-4-yl)-acetic acid tert-butyl ester → atorvastatin sodium (134523-01-6)

Conditions	Yield
Stage #1: (6-{2-[2-(4-fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrolidin-1-yl]-ethyl}-2-phenyl-[1,3,2] dioxaborinan-4-yl)-acetic acid tert-butyl ester In tetrahydrofuran for 0.5h; Stage #2: With sodium hydroxide; water In tetrahydrofuran for 2 - 4h; Product distribution / selectivity; Heating / reflux;

C34H35FN2O3 → atorvastatin sodium (134523-01-6)

Conditions	Yield
With sodium hydroxide In methanol; water; acetone at 60℃; for 0.666667h; pH=12; Product distribution / selectivity;
With sodium hydroxide In water; isopropyl alcohol; acetone at 65℃; for 0.75h; pH=11.9; Product distribution / selectivity;

atorvastatin lactone (125995-03-1) + (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid t-butyl ester (134395-00-9) → atorvastatin sodium (134523-01-6)

Conditions	Yield
With sodium hydroxide; water In methanol at 35 - 45℃; for 0.5 - 0.666667h; Product distribution / selectivity;
With sodium hydroxide; water In ethanol at 35 - 45℃; for 0.5 - 0.666667h; Product distribution / selectivity;

tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2-phenyl-1,3,2-dioxaborinan-4-yl)acetate (849928-46-7) → atorvastatin sodium (134523-01-6)

Conditions	Yield
With water; sodium hydroxide In tetrahydrofuran at 20℃; for 3h;
With water; sodium hydroxide In tetrahydrofuran at 20℃; for 3h;

tert-butyl (4S,6S)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate (472967-95-6) → atorvastatin sodium (134523-01-6)

Conditions	Yield
Stage #1: tert-butyl (4S,6S)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate With hydrogenchloride In acetonitrile at 20℃; Stage #2: With sodium hydroxide In water; acetonitrile at 20℃; Stage #3: With hydrogenchloride In water; acetonitrile pH=9.0 - 9.5; Product distribution / selectivity;

Atorvastatin boronate → atorvastatin sodium (134523-01-6)

Conditions	Yield
With sodium hydroxide In methanol; water at 100℃; for 4h;

cis-t-butyl-7-nitro-3,5-dihydroxy-heptanoate (1370478-51-5) → atorvastatin sodium (134523-01-6)

Conditions

Yield

Multi-step reaction with 7 steps 1: methanesulfonic acid / tetrahydrofuran / 0 °C 2: hydrogen; ammonia / palladium 10% on activated carbon / water; tetrahydrofuran; methanol / 6 h / 20 °C 3: triethylamine / acetonitrile / 0 - 20 °C / Inert atmosphere 4: triethylamine / dichloromethane / 0 °C / Inert atmosphere 5: acetic anhydride / 5 h / 75 - 80 °C / Inert atmosphere 6: hydrogenchloride; water / methanol / 1.5 h / 20 °C 7: sodium hydroxide; water / methanol / 0 - 20 °C / pH 12 View Scheme

cis-t-butyl-2-methoxy-3,5-dioxane-6-amino-(N-ethyl-(4-fluorobenzene)-acetate)-heptanoate → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 4 steps 1: triethylamine / dichloromethane / 0 °C / Inert atmosphere 2: acetic anhydride / 5 h / 75 - 80 °C / Inert atmosphere 3: hydrogenchloride; water / methanol / 1.5 h / 20 °C 4: sodium hydroxide; water / methanol / 0 - 20 °C / pH 12 View Scheme

cis-t-butyl-2-ethoxy-3,5-dioxane-6-amino(N,N-((4-fluorobenzene)isobutyryl)-acetic acid)-heptanoate → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 3 steps 1: acetic anhydride / 5 h / 75 - 80 °C / Inert atmosphere 2: hydrogenchloride; water / methanol / 1.5 h / 20 °C 3: sodium hydroxide; water / methanol / 0 - 20 °C / pH 12 View Scheme

cis-t-butyl-2-methoxy-3,5-dioxane-7-nitro-heptanoate → atorvastatin sodium (134523-01-6)

Conditions

Yield

Multi-step reaction with 6 steps 1: hydrogen; ammonia / palladium 10% on activated carbon / water; tetrahydrofuran; methanol / 6 h / 20 °C 2: triethylamine / acetonitrile / 0 - 20 °C / Inert atmosphere 3: triethylamine / dichloromethane / 0 °C / Inert atmosphere 4: acetic anhydride / 5 h / 75 - 80 °C / Inert atmosphere 5: hydrogenchloride; water / methanol / 1.5 h / 20 °C 6: sodium hydroxide; water / methanol / 0 - 20 °C / pH 12 View Scheme

cis-t-butyl-2-methoxy-3,5-dioxane-7-amino-heptanoate → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 5 steps 1: triethylamine / acetonitrile / 0 - 20 °C / Inert atmosphere 2: triethylamine / dichloromethane / 0 °C / Inert atmosphere 3: acetic anhydride / 5 h / 75 - 80 °C / Inert atmosphere 4: hydrogenchloride; water / methanol / 1.5 h / 20 °C 5: sodium hydroxide; water / methanol / 0 - 20 °C / pH 12 View Scheme

ethyl 7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-5-hydroxyhept-3-enoate → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 4 steps 1: 1,8-diazabicyclo[5.4.0]undec-7-ene / acetonitrile / 24 h / 20 °C 2: benzaldehyde; potassium tert-butylate / tetrahydrofuran / 1.75 h / -5 °C 3: hydrogenchloride / water; methanol; tetrahydrofuran / 3 h / 50 °C 4: sodium hydroxide; water / 15 h / 20 °C View Scheme

ethyl 2-[6-{2-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1Hpyrrol-1-yl]ethyl}-2-phenyl-1,3-dioxan-4-yl]acetate → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 3 steps 1: hexane; isopropyl alcohol / 50 - 60 °C 2: hydrogenchloride / water; methanol; tetrahydrofuran / 3 h / 50 °C 3: sodium hydroxide; water / 15 h / 20 °C View Scheme

C35H37FN2O4 → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 3 steps 1: benzaldehyde; potassium tert-butylate / tetrahydrofuran / 1.75 h / -5 °C 2: hydrogenchloride / water; methanol; tetrahydrofuran / 3 h / 50 °C 3: sodium hydroxide; water / 15 h / 20 °C View Scheme

ethyl 2-[(2R,4R,6R)-6-{2-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1Hpyrrol-1-yl]ethyl}-2-phenyl-1,3-dioxan-4-yl]acetate → atorvastatin sodium (134523-01-6)

Conditions	Yield
Multi-step reaction with 2 steps 1: hydrogenchloride / water; methanol; tetrahydrofuran / 3 h / 50 °C 2: sodium hydroxide; water / 15 h / 20 °C View Scheme

atorvastatin sodium (134523-01-6) → atorvastatin (134523-00-5)

Conditions	Yield
With sodium hydroxide at 60 - 70℃; pH=12-13;	95%
With hydrogenchloride In dichloromethane; water for 0.5h; Cooling with ice;	94%

atorvastatin sodium (134523-01-6) → lipitor (134523-03-8)

Conditions	Yield
With calcium acetate In water at 20℃; for 2h;	93%
With calcium acetate In methanol; water at 60 - 65℃; for 2h; Industrial scale;	85.4%
With calcium acetate In water at 13 - 63℃;

methanol (67-56-1) + atorvastatin sodium (134523-01-6) → (3R,5R)-methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate (345891-62-5)

Conditions	Yield
With sulfuric acid at 0 - 20℃; for 2.58333h;	88%

atorvastatin sodium (134523-01-6) + hexan-1-ol (111-27-3) → hexyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate

Conditions	Yield
With sulfuric acid In dichloromethane at 0 - 20℃; for 2.58333h;	70%

ethanol (64-17-5) + atorvastatin sodium (134523-01-6) → ethyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate (1146977-93-6)

Conditions	Yield
With sulfuric acid at 0 - 20℃; for 2.58333h;	68%

atorvastatin sodium (134523-01-6) + butan-1-ol (71-36-3) → butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate

Conditions	Yield
With sulfuric acid In dichloromethane at 0 - 20℃; for 2.58333h;	59%

atorvastatin sodium (134523-01-6) → {[R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid} hemi-magnesium salt

Conditions	Yield
With magnesium chloride In tert-butyl methyl ether; water for 1.41667h;
With hydrogenchloride; magnesium acetate In water; acetone at 25 - 45℃; for 73.5h; pH=8 - 8.5; Product distribution / selectivity;

atorvastatin sodium (134523-01-6) → [R-(RS,RS)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid iron salt

Conditions	Yield
With iron(II) sulfate In water at 40 - 45℃; for 1h; Product distribution / selectivity;
With iron(II) chloride In water at 40 - 45℃; for 2h; Product distribution / selectivity;

calcium acetate (62-54-4) + atorvastatin sodium (134523-01-6) → lipitor (134523-03-8)

Conditions	Yield
In methanol; water at 13 - 63℃; Product distribution / selectivity;

atorvastatin sodium (134523-01-6) → atorvastatin hemicalcium

Conditions	Yield
With calcium chloride In water at 35 - 45℃; for 0.166667 - 0.5h; Product distribution / selectivity;
With calcium acetate In methanol; water at 50℃;
With calcium chloride In methanol; tert-butyl methyl ether; water at 25 - 30℃; pH=7.5 - 8.5; Product distribution / selectivity;

Upstream product

• 125971-94-0 2-((4R, 6R)-6-cyanomethyl-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid tert-butyl ester 
• 1146977-93-6 ethyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 1370478-51-5 cis-t-butyl-7-nitro-3,5-dihydroxy-heptanoate 
• 472967-95-6 tert-butyl (4S,6S)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate 
• 849928-46-7 tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2-phenyl-1,3,2-dioxaborinan-4-yl)acetate 
• 125995-03-1 atorvastatin lactone 
• 134395-00-9 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid t-butyl ester 
• 134523-00-5 atorvastatin 
• 697266-12-9 [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-di(tert-butyldimethylsiloxy)-5-(1-methylethyl)-3-phenyl-4-[(pheny)carbonyl]-1H-pyrrole-1-heptanoic acid test-butyl ester 
• 125971-95-1 tert-butyl (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate 
• 125971-96-2 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxopentanoic acid phenylamide 
• 125971-86-0 tert-butyl [(4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 134523-03-8 lipitor 
• 134523-00-5 atorvastatin 
• 1146977-93-6 ethyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 345891-62-5 (3R,5R)-methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 

Relevant articles and documents

PROCESS FOR THE CONTINUOUS MANUFACTURE OF STATINS

The present invention relates to process for the continuous manufacture of Statins or salts thereof. The present invention relates to process for the continuous manufacture of Atorvastatin or a salt thereof. The present invention relates to a continuous m

Method for purifying atorvastatin calcium intermediate

The atorvastatin calcium intermediate is subjected to hydrolysis reaction to obtain the reaction liquid of atorvastatin calcium intermediate. The reaction liquid is extracted with a stripping solvent and is separated and separated to obtain an aqueous pha

AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF PYRROLE DERIVATIVES WITH IMPROVED IMPURITY PROFILE & MINIMISATION OF UNIT OPERATIONS.

The present invention relates to improved process for the preparation of a pyrrole derivative as a racemic mixture, an enantiomer, a diastereoisomer, a mixture thereof, a tautomer thereof or a pharmaceutically acceptable salt and hydrates thereof and also intermediates involved therein. Particularly invention is directed to improved processes for the preparation of pyrrole derivatives such as (4R,cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluorophenyl)-5-(1-methyl-ethyl)-pyrrole-1-yl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of formula IV followed by its conversion into [R-(R*, R*]-2-(4-fluorophenyl)- β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid particularly calcium salt and its hydrate represented by Formulae I/IA respectively wherein formation of the impurities is either eliminated or minimized in the corresponding intermediaries.

Preparation method of crystal form I atorvastatin calcium

The invention discloses a preparation method of crystal form I atorvastatin calcium. The method includes the steps of: preparation of atorvastatin ester; preparation of an atorvastatin salt; preparation of atorvastatin calcium; refining an atorvastatin ca

Preparing method of high-purity atorvastatin calcium

The invention discloses a preparing method of high-purity atorvastatin calcium, and belongs to the technical field of organic synthesis. The method includes the steps of making a compound V and calcium acetate react in a water and alcohol mixed solvent system, and conducting cooling crystallization and filtration after the reaction is completed to obtain an atorvastatin calcium crude product, wherein the reaction temperature is 40-70 DEG C, the volume ratio of alcohols to water in the reaction system is 1:(2-8), and the mass percentage concentration of the compound V in a mixed solvent is 5-10%; dissolving the atorvastatin calcium crude product in a recrystallization solvent A, adding I-type atorvastatin calcium crystals at 45-85 DEG C for crystal transformation, and conducting cooling crystallization, filtration, washing and drying after crystal transformation is completed to obtain a fine product, wherein the mass percentage concentration of the atorvastatin calcium crude product inthe recrystallization solvent A is 5-10%. The method has the advantages of being high in product purity, easy and safe to operate, high in yield and the like and is suitable for large-scale industrialproduction.

Synthesis method of atorvastatin calcium

The invention relates to a synthesis method of an atorvastatin calcium. A cheap and easy-to-get Paal-Knorr cyclization product formula-V compound is subjected to hydroxyl deprotection, esterolysis andsalinization so as to obtain a target product atorvasta

Enantioselective synthesis of allylboronates and allylic alcohols by copper-catalyzed 1,6-boration

Chiral secondary allylboronates are obtained in high enantioselectivities and 1,6:1,4 ratios by the copper-catalyzed 1,6-boration of electron-deficient dienes with bis(pinacolato)diboron (B2(pin)2). The reactions proceed efficiently using catalyst loadings as low as 0.0049 mol %. The allylboronates may be oxidized to the allylic alcohols, and can be used in stereoselective aldehyde allylborations. This process was applied to a concise synthesis of atorvastatin, in which the key 1,6-boration was performed using only a 0.02 mol % catalyst loading. 1,6-Borations of electron-deficient dienes with bis(pinacolato)diboron using copper catalyst loadings as low as 0.0049 mol % provided chiral allylboronates that, after oxidation, result in allylic alcohols in high enantioselectivities and 1,6:1,4 ratios. The allylboronates can also be used in stereoselective allylations of aldehydes. This process was applied to a concise synthesis of atorvastatin.

Spectroscopic characterization and quantitative determination of atorvastatin calcium impurities by novel HPLC method

Seven process related impurities were identified by LC-MS in the atorvastatin calcium drug substance. These impurities were identified by LC-MS. The structure of impurities was confirmed by modern spectroscopic techniques like 1H NMR and IR and physicochemical studies conducted by using synthesized authentic reference compounds. The synthesized reference samples of the impurity compounds were used for the quantitative HPLC determination. These impurities were detected by newly developed gradient, reverse phase high performance liquid chromatographic (HPLC) method. The system suitability of HPLC analysis established the validity of the separation. The analytical method was validated according to International Conference of Harmonization (ICH) with respect to specificity, precision, accuracy, linearity, robustness and stability of analytical solutions to demonstrate the power of newly developed HPLC method.

Spectroscopic characterization and quantitative determination of atorvastatin calcium impurities by novel HPLC method

Seven process related impurities were identified by LC-MS in the atorvastatin calcium drug substance. These impurities were identified by LC-MS. The structure of impurities was confirmed by modern spectroscopic techniques like 1H NMR and IR and physicochemical studies conducted by using synthesized authentic reference compounds. The synthesized reference samples of the impurity compounds were used for the quantitative HPLC determination. These impurities were detected by newly developed gradient, reverse phase high performance liquid chromatographic (HPLC) method. The system suitability of HPLC analysis established the validity of the separation. The analytical method was validated according to International Conference of Harmonization (ICH) with respect to specificity, precision, accuracy, linearity, robustness and stability of analytical solutions to demonstrate the power of newly developed HPLC method.

PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN

The present invention relates to a preparation process useful in synthesis of atorvastatin, more particularly a process for preparing atorvastatin is effective in treating hyperlipemia, comprising protecting the dihydroxy group at C3 and C5 positions of t